Table of Contents

company-logo

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BioXcel Therapeutics Dividend Announcement

• BioXcel Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on BioXcel Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

BioXcel Therapeutics Dividend History

BioXcel Therapeutics Dividend Yield

BioXcel Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing BioXcel Therapeutics stock? Use our calculator to estimate your expected dividend yield:

BioXcel Therapeutics Financial Ratios

P/E ratio-0.27
PEG ratio0.01
P/B ratio-0.39
ROE176.93%
Payout ratio0.00%
Current ratio2.35
Quick ratio2.25
Cash Ratio2.06

BioXcel Therapeutics Dividend FAQ

Does BioXcel Therapeutics stock pay dividends?
BioXcel Therapeutics does not currently pay dividends to its shareholders.
Has BioXcel Therapeutics ever paid a dividend?
No, BioXcel Therapeutics has no a history of paying dividends to its shareholders. BioXcel Therapeutics is not known for its dividend payments.
Why doesn't BioXcel Therapeutics pay dividends?
There are several potential reasons why BioXcel Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will BioXcel Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While BioXcel Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is BioXcel Therapeutics a dividend aristocrat?
BioXcel Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is BioXcel Therapeutics a dividend king?
BioXcel Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is BioXcel Therapeutics a dividend stock?
No, BioXcel Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy BioXcel Therapeutics stocks?
To buy BioXcel Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy BioXcel Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.